Theravance Biopharma (TBPH) Change in Acquisitions & Divestments (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Change in Acquisitions & Divestments data on file, last reported at $96.0 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 194.48% year-over-year to $96.0 million in Q1 2026; TTM through Mar 2026 was $206.4 million, a 60.74% increase from a year earlier, with the FY2025 full-year figure at $143.0 million, up 2.26% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $96.0 million, up from $65.5 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for TBPH reached as high as $96.0 million in Q1 2026 and fell as low as -$108.7 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $25.6 million across 5 years, with a median of $30.4 million in 2024.
• Across the five-year window, Change in Acquisitions & Divestments sank 267.72% in 2022 and soared 226.06% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at -$108.7 million in 2022, then soared by 63.25% to -$39.9 million in 2023, then jumped by 200.27% to $40.1 million in 2024, then jumped by 63.6% to $65.5 million in 2025, then soared by 46.51% to $96.0 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $96.0 million in Q1 2026, $65.5 million in Q4 2025, and $24.5 million in Q3 2025.